Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

NCT05502315 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Castration-resistant Prostate Cancer
Metastatic Cancer

Interventions

DRUG: Cabozantinib
DRUG: Nivolumab

Sponsor

Rana McKay, MD

Collaborators

[object Object]
[object Object]